RT Journal Article
SR Electronic
T1 Weekly Chemotherapy with Cisplatin and Paclitaxel in Inoperable Non-small Cell Lung Cancer: An Extended Phase II Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4685
OP 4692
VO 25
IS 6C
A1 DOMENICO FERRIGNO
A1 GIANFRANCO BUCCHERI
YR 2005
UL http://ar.iiarjournals.org/content/25/6C/4685.abstract
AB Background: A phase II study of a cisplatin/paclitaxel combination given on a weekly schedule in the front-line treatment of non-small cell lung cancer (NSCLC) is reported. Patients and Methods: Treatment consisted of an intravenous infusion of cisplatin, 25 mg/m2, and paclitaxel, 80 mg/m2, every week. Chemotherapy was continued until completion of a 22-week treatment plan, disease progression, persistent toxicity, or patient refusal. Results: Seventy-nine patients entered the study. The median number of infusions per patient was 14 (range 0-22). The median dose-intensity was 75% of that projected. Toxicity was generally acceptable, and never life-threatening. Seven complete responses (pathologically documented in 4 patients) and 27 partial responses were observed for an overall response rate of 43%. The estimated median survival and median time to progression was 55 (95% CI: 38-71) and 37 weeks (95% CI: 31-44), respectively. Conclusion: In our experience, the weekly combination of cisplatin and paclitaxel is well tolerated, active and associated with remarkably long survivals. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved